<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_vesicles" title="Extracellular Vesicles as Natural, Safe and Efficient Drug Delivery Systems" shortTitle="vesicles" author="Federico Villa, Rodolfo Quarto, Roberta Tasso" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1999-4923/11/11/557/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Extracellular	JJ	Extracellular
vesicles	NNS	vesicle
(	-LRB-	(
EVs	NNS	EV
)	-RRB-	)
are	VBP	be
cell-derived	VBN	cell-derive
membrane	NN	membrane
vesicles	NNS	vesicle
that	WDT	that
represent	VBP	represent
an	DT	a
endogenous	JJ	endogenous
mechanism	NN	mechanism
for	IN	for
intercellular	JJ	intercellular
communication	NN	communication
.	.	.
</s>
<s type="sub">
EVs	NNS	EV
can	MD	can
be	VB	be
classified	VBN	classify
in	IN	in
exosomes	NNS	exosome
,	,	,
nano-sized	JJ	nano-sized
vesicles	NNS	vesicle
(	-LRB-	(
with	IN	with
a	DT	a
diameter	NN	diameter
in	IN	in
the	DT	the
range	NN	range
of	IN	of
30	CD	30
to	IN	to
120	CD	120
nm	NN	nm
)	-RRB-	)
,	,	,
that	WDT	that
originate	VBP	originate
from	IN	from
the	DT	the
cell	NN	cell
endocytic	JJ	endocytic
compartment	NN	compartment
through	IN	through
the	DT	the
formation	NN	formation
of	IN	of
multivesicular	JJ	multivesicular
bodies	NNS	body
(	-LRB-	(
MVB	NNP	MVB
)	-RRB-	)
,	,	,
microvesicles	NNS	microvesicle
,	,	,
with	IN	with
a	DT	a
diameter	NN	diameter
up	IN	up
to	IN	to
1	CD	1
μm	NN	im
released	VBN	release
by	IN	by
cell	NN	cell
membrane	NN	membrane
budding	NN	budding
,	,	,
and	CC	and
apoptotic	JJ	apoptotic
bodies	NNS	body
,	,	,
with	IN	with
a	DT	a
dimension	NN	dimension
similar	JJ	similar
to	IN	to
platelets	NNS	platelet
,	,	,
derived	VBN	derive
from	IN	from
blebbing	NN	blebbing
of	IN	of
dying	VBG	die
cells	NNS	cell
.	.	.
</s>
<s type="decl">
Despite	IN	despite
the	DT	the
distinct	JJ	distinct
sizes	NNS	size
and	CC	and
biogenesis	NN	biogenesis
,	,	,
the	DT	the
absence	NN	absence
of	IN	of
standardized	VBN	standardize
isolation	NN	isolation
methods	NNS	method
and	CC	and
the	DT	the
numerous	JJ	numerous
similarities	NNS	similarity
existing	VBG	exist
between	IN	between
these	DT	this
two	CD	2
subclasses	NNS	subclass
make	VBP	make
it	PRP	it
particularly	RB	particularly
challenging	JJ	challenging
to	TO	to
distinguish	VB	distinguish
among	IN	among
them	PRP	they
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
review	NN	review
,	,	,
we	PRP	we
will	MD	will
use	VB	use
the	DT	the
generic	JJ	generic
term	NN	term
EVs	NN	EV
to	TO	to
indicate	VB	indicate
both	CC	both
exosomes	NNS	exosome
and	CC	and
microvesicles	NNS	microvesicle
.	.	.
</s>
</p>
<p>
<s type="decl">
EVs	NNS	EV
have	VBP	have
been	VBN	be
shown	VBN	show
to	TO	to
carry	VB	carry
functionally	RB	functionally
active	JJ	active
biological	JJ	biological
materials	NNS	material
including	VBG	include
proteins	NNS	protein
,	,	,
mRNAs	NNS	mrna
and	CC	and
miRNAs	NNS	mirna
,	,	,
which	WDT	which
makes	VBZ	make
them	PRP	they
capable	JJ	capable
of	IN	of
transmitting	VBG	transmit
signals	NNS	signal
to	IN	to
target	JJ	target
cells	NNS	cell
in	IN	in
the	DT	the
surrounding	VBG	surround
environment	NN	environment
as	RB	as
well	RB	well
as	IN	as
to	IN	to
distant	JJ	distant
organs	NNS	organ
,	,	,
via	IN	via
blood	NN	blood
and	CC	and
lymphatic	JJ	lymphatic
vessels	NNS	vessel
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
scientific	JJ	scientific
community	NN	community
has	VBZ	have
recently	RB	recently
turned	VBN	turn
its	PRP$	its
interest	NN	interest
toward	IN	toward
the	DT	the
evaluation	NN	evaluation
of	IN	of
EVs	NNS	EV
as	IN	as
drug	NN	drug
delivery	NN	delivery
vehicles	NNS	vehicle
.	.	.
</s>
<s type="decl">
In	IN	in
this	DT	this
context	NN	context
,	,	,
EVs	NNS	EV
offer	VBP	offer
significant	JJ	significant
advantages	NNS	advantage
over	IN	over
current	JJ	current
drug	NN	drug
delivery	NN	delivery
systems	NNS	system
,	,	,
such	JJ	such
as	IN	as
liposomes	NNS	liposome
and	CC	and
polymeric	JJ	polymeric
nanoparticles	NNS	nanoparticle
.	.	.
</s>
<s type="decl">
Since	IN	since
EVs	NNPS	EVs
can	MD	can
be	VB	be
obtained	VBN	obtain
with	IN	with
an	DT	a
autologous	JJ	autologous
procedure	NN	procedure
from	IN	from
the	DT	the
patient	NN	patient
’s	POS	's
cells	NNS	cell
or	CC	or
blood	NN	blood
,	,	,
they	PRP	they
do	VBP	do
not	RB	not
solicit	VB	solicit
the	DT	the
immune	JJ	immune
system	NN	system
as	IN	as
usual	JJ	usual
synthetic	JJ	synthetic
formulations	NNS	formulation
do	VBP	do
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
given	VBN	give
their	PRP$	their
phospholipid	NN	phospholipid
bilayer	NN	bilayer
,	,	,
EVs	NNP	EVs
can	MD	can
directly	RB	directly
fuse	VB	fuse
with	IN	with
the	DT	the
targeted	VBN	target
plasma	NN	plasma
membrane	NN	membrane
,	,	,
thus	RB	thus
allowing	VBG	allow
a	DT	a
more	RBR	more
efficient	JJ	efficient
internalization	NN	internalization
of	IN	of
the	DT	the
encapsulated	JJ	encapsulated
drug	NN	drug
.	.	.
</s>
<s type="decl">
Their	PRP$	their
hydrophilic	JJ	hydrophilic
shell	NN	shell
,	,	,
together	RB	together
with	IN	with
the	DT	the
presence	NN	presence
of	IN	of
anti-phagocytosis	JJ	anti-phagocytosis
surface	NN	surface
markers	NNS	marker
(	-LRB-	(
i.e.	FW	i.e.
,	,	,
CD47	FW	CD47
)	-RRB-	)
,	,	,
enables	VBZ	enable
them	PRP	they
to	TO	to
evade	VB	evade
phagocytosis	NN	phagocytosis
by	IN	by
monocytes	NNS	monocyte
and	CC	and
macrophages	NNS	macrophage
of	IN	of
the	DT	the
reticulo-endothelial	JJ	reticulo-endothelial
system	NN	system
,	,	,
hence	RB	hence
weakening	VBG	weaken
their	PRP$	their
clearance	NN	clearance
.	.	.
</s>
<s type="decl">
Moreover	RB	moreover
,	,	,
the	DT	the
limited	JJ	limited
size	NN	size
allows	VBZ	allow
them	PRP	they
to	TO	to
efficiently	RB	efficiently
extravasate	VB	extravasate
through	IN	through
the	DT	the
inter-endothelial	JJ	inter-endothelial
junctions	NNS	junction
and	CC	and
fenestrations	NNS	fenestration
of	IN	of
both	CC	both
existing	VBG	exist
and	CC	and
neo-synthesized	JJ	neo-synthesized
vessels	NNS	vessel
.	.	.
</s>
<s type="sub">
Thanks	NNS	thanks
to	IN	to
these	DT	this
peculiar	JJ	peculiar
characteristics	NNS	characteristic
,	,	,
they	PRP	they
can	MD	can
spread	VB	spread
and	CC	and
accumulate	VB	accumulate
in	IN	in
the	DT	the
parenchyma	NN	parenchyma
of	IN	of
solid	JJ	solid
tumors	NNS	tumor
.	.	.
</s>
<s type="frag">
EV	NNP	EV
</s>
<s type="decl">
biological	JJ	biological
properties	NNS	property
derive	VBP	derive
from	IN	from
their	PRP$	their
sophisticated	JJ	sophisticated
membrane	NN	membrane
structure	NN	structure
,	,	,
characterized	VBN	characterize
by	IN	by
the	DT	the
presence	NN	presence
of	IN	of
several	JJ	several
proteins	NNS	protein
for	IN	for
active	JJ	active
targeting	NN	targeting
,	,	,
adhesion	NN	adhesion
,	,	,
cell	NN	cell
fusion	NN	fusion
,	,	,
and	CC	and
intracellular	JJ	intracellular
release	NN	release
of	IN	of
their	PRP$	their
content	NN	content
;	:	;
this	DT	this
functional	JJ	functional
complexity	NN	complexity
is	VBZ	be
not	RB	not
easily	RB	easily
reproduced	VBN	reproduce
by	IN	by
de	NNP	de
novo	RB	novo
synthesized	VBN	synthesize
nanoparticles	NNS	nanoparticle
.	.	.
</s>
<s type="decl">
Among	IN	among
the	DT	the
several	JJ	several
types	NNS	type
of	IN	of
nano-based	JJ	nano-based
drug	NN	drug
delivery	NN	delivery
systems	NNS	system
,	,	,
liposomes	NNS	liposome
are	VBP	be
probably	RB	probably
the	DT	the
most	RBS	most
used	VBN	use
,	,	,
due	JJ	due
to	IN	to
their	PRP$	their
non-toxicity	NN	non-toxicity
and	CC	and
capacity	NN	capacity
to	TO	to
accommodate	VB	accommodate
high	JJ	high
amounts	NNS	amount
of	IN	of
compounds	NNS	compound
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
a	DT	a
still	RB	still
inadequate	JJ	inadequate
in	IN	in
vivo	NN	vivo
targeting	NN	targeting
efficiency	NN	efficiency
together	RB	together
with	IN	with
a	DT	a
potential	JJ	potential
immunogenicity	NN	immunogenicity
associated	VBN	associate
to	IN	to
liposomal	NN	liposomal
formulations	NNS	formulation
has	VBZ	have
limited	VBN	limit
their	PRP$	their
broad	JJ	broad
applicability	NN	applicability
in	IN	in
therapeutics	NNS	therapeutics
.	.	.
</s>
</p>
<p>
<s type="decl">
Therefore	RB	therefore
,	,	,
the	DT	the
greater	JJR	great
specificity	NN	specificity
combined	VBN	combine
with	IN	with
the	DT	the
consequent	JJ	consequent
limited	JJ	limited
induction	NN	induction
of	IN	of
systemic	JJ	systemic
side	NN	side
effects	NNS	effect
make	VBP	make
EVs	NNS	EV
ideal	JJ	ideal
vehicles	NNS	vehicle
for	IN	for
drug	NN	drug
delivery	NN	delivery
.	.	.
</s>
<s type="decl">
Although	IN	although
this	DT	this
research	NN	research
field	NN	field
is	VBZ	be
in	IN	in
its	PRP$	its
infancy	NN	infancy
,	,	,
in	IN	in
the	DT	the
last	JJ	last
decade	NN	decade
,	,	,
the	DT	the
use	NN	use
of	IN	of
bio-engineered	JJ	bio-engineered
EVs	NNS	EV
for	IN	for
the	DT	the
delivery	NN	delivery
of	IN	of
cytotoxic	JJ	cytotoxic
molecules	NNS	molecule
in	IN	in
preclinical	JJ	preclinical
models	NNS	model
has	VBZ	have
produced	VBN	produce
encouraging	VBG	encourage
results	NNS	result
.	.	.
</s>
<s type="decl">
These	DT	this
experimental	JJ	experimental
evidences	NNS	evidence
,	,	,
in	IN	in
addition	NN	addition
to	IN	to
preliminary	JJ	preliminary
clinical	JJ	clinical
data	NNS	datum
,	,	,
indicate	VBP	indicate
that	IN	that
EV	NN	EV
formulations	NNS	formulation
may	MD	may
not	RB	not
only	RB	only
enhance	VB	enhance
the	DT	the
safety	NN	safety
and	CC	and
biodistribution	NN	biodistribution
of	IN	of
commonly	RB	commonly
used	VBN	use
drugs	NNS	drug
,	,	,
but	CC	but
also	RB	also
increase	VB	increase
their	PRP$	their
efficacy	NN	efficacy
.	.	.
</s>
<s type="decl">
For	IN	for
example	NN	example
,	,	,
it	PRP	it
has	VBZ	have
been	VBN	be
demonstrated	VBN	demonstrate
that	IN	that
the	DT	the
administration	NN	administration
of	IN	of
EV-encapsulating	NNP	EV-encapsulating
chemotherapy	NN	chemotherapy
drugs	NNS	drug
leads	VBZ	lead
to	IN	to
a	DT	a
significant	JJ	significant
reduction	NN	reduction
of	IN	of
drug	NN	drug
accumulation	NN	accumulation
in	IN	in
off-target	JJ	off-target
organs	NNS	organ
,	,	,
thus	RB	thus
preventing	VBG	prevent
important	JJ	important
side	NN	side
effects	NNS	effect
during	IN	during
standard	JJ	standard
clinical	JJ	clinical
protocols	NNS	protocol
.	.	.
</s>
<s type="decl">
An	DT	a
astonishing	JJ	astonish
number	NN	number
of	IN	of
newly	RB	newly
published	VBN	publish
papers	NNS	paper
perfectly	RB	perfectly
depict	VBP	depict
the	DT	the
scientific	JJ	scientific
community	NN	community
’s	POS	's
authentic	JJ	authentic
interest	NN	interest
in	IN	in
this	DT	this
flourishing	VBG	flourish
research	NN	research
field	NN	field
.	.	.
</s>
</p>
<p>
<s type="decl">
Nevertheless	RB	nevertheless
,	,	,
the	DT	the
first	JJ	first
aim	NN	aim
of	IN	of
this	DT	this
review	NN	review
is	VBZ	be
to	TO	to
disclose	VB	disclose
an	DT	a
overview	NN	overview
of	IN	of
the	DT	the
latest	JJS	late
applications	NNS	application
of	IN	of
EVs	NNS	EV
as	IN	as
drug	NN	drug
delivery	NN	delivery
vehicles	NNS	vehicle
,	,	,
focusing	VBG	focus
on	IN	on
the	DT	the
sources	NNS	source
employed	VBN	employ
,	,	,
the	DT	the
molecules	NNS	molecule
selected	VBN	select
,	,	,
and	CC	and
the	DT	the
final	JJ	final
intended	VBN	intend
targets	NNS	target
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
second	JJ	second
part	NN	part
of	IN	of
the	DT	the
review	NN	review
,	,	,
we	PRP	we
will	MD	will
take	VB	take
a	DT	a
step	NN	step
back	RB	back
and	CC	and
bring	VB	bring
attention	NN	attention
to	IN	to
the	DT	the
basics	NNS	basic
of	IN	of
one	CD	one
of	IN	of
the	DT	the
main	JJ	main
pitfalls	NNS	pitfall
concerning	VBG	concern
EVs	NN	EV
:	:	:
the	DT	the
urgent	JJ	urgent
need	NN	need
for	IN	for
highly	RB	highly
pure	JJ	pure
vesicle	NN	vesicle
preparation	NN	preparation
.	.	.
</s>
</p>
</text>